12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Company News  |  Deals

Isis Pharmaceuticals, KineMed, CHDI Foundation Inc. deal

Isis will use biomarkers from KineMed and the not-for-profit foundation to develop an antisense therapeutic for Huntington's disease (HD). KineMed and the foundation are partnered to use KineMed's isotopic labeling...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >